Mayne-Sun US Settlement Keeps Generic Imvexxy Out Til 2032

By Antony Scholefield · September 30, 2026, 4:40 PM AEST

ASX-listed Mayne Pharma announced a settlement in a US patent dispute with Sun Pharmaceuticals Industries Ltd. on Wednesday over an oestradiol vaginal insert used to treat symptoms of menopause, with Sun...

To view the full article, register now.

Try Law360 Australia FREE for fourteen days

Already a subscriber? Click here to login

Documents

Statement

Related Sections

Commercial Disputes AU

Already have access? Click here to login

Get instant access to the one-stop news source for business lawyers

Sign up now for an exclusive preview

Email (NOTE: Free email domains not supported)

First Name

Last Name

Phone Number

PLEASE NOTE: A verification email will be sent to your address before you can access your trial.

Password (at least 8 characters required)

Confirm Password

Job Title

Select at least one primary interest:

Commercial Disputes AU

Financial Services AU

Law360 Australia may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.

You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.

We take your privacy seriously. Please see our Privacy Policy.

Start Reading

Already have access?

Email:
Password: Forgot your password?
Remember login
Sign In

Sign up for our Commercial Disputes AU newsletter

You must correct or enter the following before you can sign up:

Please provide a professional email:

Select more newsletters to receive for free

Commercial Disputes AU

Financial Services AU

Law360 Australia takes your privacy seriously. Please see our Privacy Policy.